Structure-based design and computational screening of Fyn kinase inhibitors targeting neurodegenerative pathways in Alzheimer's disease
Abstract
Fyn kinase, a non-receptor tyrosine kinase, plays a crucial role in various cellular processes and is implicated in diseases like neurodegenerative disorders and cancer. The present study employed a structure-based virtual screening approach utilising a pharmacophore model derived from the known inhibitor staurosporine to identify potential therapeutic agents. MolPort, a large chemical database, was screened to obtain 1,127 initial hits, which were filtered based on drug-likeness, PAINS, pharmacokinetic properties, and toxicity profiles, resulting in 104 promising compounds. Molecular docking of these compounds against the Fyn kinase ATP-binding site identified two top-ranking candidates, MolPort-000-414-107 and MolPort-005-915-880, exhibiting favourable binding energies and stable binding poses. To further evaluate the stability and dynamics of these interactions, 200 ns molecular dynamics simulations were performed. The simulations revealed that both ligands maintained stable binding within the Fyn kinase active site, with minimal RMSD fluctuations. Ligand binding led to a general reduction in protein flexibility and solvent accessibility. Hydrogen bond analysis highlighted distinct interaction patterns for each ligand, indicating different binding modes. MM-GBSA calculations predicted favourable binding free energies for both compounds, suggesting strong binding affinities. These in silico findings suggest that MolPort-000-414-107 and MolPort-005-915-880 are promising lead compounds for development of novel Fyn kinase inhibitors.